Carolyn Denney, MD
Infectious Disease · Hollywood, FLNPI 1114998796
Payments from drug & device makers
Across 654 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$3K
- Johnson & Johnson$1K
- Merck$1K
- AbbVie$1K
- Insmed, Inc.$816
- plus $4K from 25 others
What the payments were for
- Food & beverage$16,39598%
- Education$3402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 175 | $5,489 |
| Gilead | 119 | $3,139 |
| Johnson & Johnson | 73 | $1,268 |
| Merck | 49 | $1,142 |
| AbbVie(2 entities) | 37 | $1,026 |
| Insmed, Inc. | 33 | $816 |
| Paratek Pharmaceuticals, Inc. | 29 | $552 |
| Amgen | 24 | $446 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $314 |
| Novo Nordisk | 12 | $276 |
| Janssen Products, LP | 3 | $245 |
| Pfizer | 7 | $227 |
| Novartis | 7 | $178 |
| EMD Serono, Inc. | 3 | $170 |
| Kowa Pharmaceuticals America, Inc. | 9 | $169 |
| Idorsia Pharmaceuticals US Inc | 8 | $159 |
| Theratechnologies Inc. | 6 | $145 |
| Melinta Therapeutics, LLC | 7 | $142 |
| Astellas Pharma US Inc | 3 | $133 |
| Lilly USA, LLC | 7 | $124 |
| Exact Sciences | 5 | $113 |
| Aimmune Therapeutics, Inc. | 5 | $110 |
| GSK | 5 | $91 |
| Nabriva Therapeutics, PLC | 2 | $49 |
| Optinose US, Inc. | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| La Jolla Pharmaceutical Company | 2 | $40 |
| Dexcom, Inc. | 1 | $28 |
| Seqirus USA Inc | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,735 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 119 | $382,362 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 89 | $337,788 |
| JulucaDolutegravir/Rilpivirine | 42 | $171,386 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 31 | $144,103 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 35 | $139,838 |
| OzempicSemaglutide | 81 | $72,226 |
| MounjaroTirzepatide | 59 | $59,260 |
| EliquisApixaban | 63 | $52,685 |
| Repatha SureclickEvolocumab | 50 | $29,409 |
| TivicayDolutegravir Sodium | 11 | $24,787 |
| FarxigaDapagliflozin Propanediol | 16 | $20,973 |
| VascepaIcosapent Ethyl | 30 | $15,868 |
| JardianceEmpagliflozin | 15 | $10,993 |
| Ezetimibe | 138 | $3,860 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 12 | $3,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Juluca, Tivicay | $5,489 | $578,534172 claims |
| GileadBiktarvy | $3,139 | $337,78889 claims |
| Janssen Products, LPSymtuza | $245 | $144,10331 claims |
| Novo NordiskOzempic | $276 | $72,22681 claims |
| Lilly USA, LLCMounjaro | $124 | $59,26059 claims |
| PfizerEliquis, Paxlovid | $227 | $54,11496 claims |
| AstraZenecaFarxiga | $13 | $20,97316 claims |
| GSKArexvy | $91 | $3,63912 claims |
| AbbVieSynthroid | $1,026 | $3,31027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Hollywood
- Moti RamgopalFort Pierce$13.5M
- Larry BushAtlantis$9.3M
- Olayemi OsiyemiWest Palm Beach$8.8M
- Charlotte-Paige RolleOrlando$6M
- Edwin DejesusOrlando$5.9M
- Dushyantha JayaweeraMiami$5.1M
- Federico HinestrosaOrlando$5.1M
- Godson OguchiOrange City$5M
- Ammara MushtaqGainesville$2.7M
- Efrain GarciaMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.